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Clinical experience with two physiologic bicarbonate/lactate
peritoneal dialysis solutions in automated peritoneal dialysis.
Background. Patients on automated peritoneal dialysis
(APD) usually receive larger volumes of dialysis solution and
more frequent, shorter exchanges than patients on continu-
ous ambulatory peritoneal dialysis (CAPD), and therefore are
likely to derive greater benefit from more physiologic solutions.
Methods. Peritoneal dialysis solutions containing 25 mmol/L
bicarbonate and either 10 or 15 mmol/L lactate were com-
pared with standard lactate solutions (35 or 40 mmol/L) in two
prospective, open-label studies of patients on APD. Each study
included a 2-week baseline period (lactate solution), a 6-week
treatment period (bicarbonate/lactate solution), and a 2-week
follow-up period (same lactate solution as baseline). Biochemi-
cal analyses and assessments of vital signs and safety parameters
were conducted at baseline, every 2 weeks during treatment, and
at the end of the follow-up period. A product use questionnaire
was administered in one study at the end of treatment.
Results. A statistically significant rise in plasma bicarbon-
ate (approximately 2 mmol/L) occurred when patients switched
from a lactate solution to the bicarbonate/lactate solution with
equimolar buffer concentration (P < 0.001 for each solution).
Plasma bicarbonate decreased by 1.16 mmol/L after a switch
from lactate 40 mmol/L to bicarbonate/lactate 35 mmol/L (P <
0.001). When patients switched to bicarbonate/lactate 35, the
majority of individual venous plasma bicarbonate values were
in the normal range. A switch from a lower calcium (1.25 mmol/
L) lactate solution to a higher calcium (1.75 mmol/L) lac-
tate/bicarbonate solution resulted in a statistically significant
rise in serum calcium (0.06 mmol/L, P < 0.018). The product
use questionnaire revealed improvements in symptoms, includ-
ing reduced pain on infusion.
Conclusion. Bicarbonate/lactate solutions may be used safely
and effectively in patients on APD. The availability of 2 for-
mulations with different buffer and calcium content provides
flexibility for the control of acidosis as well as calcium balance.
Bicarbonate has been used in hemodialysis for many
years, as it is one of the few systems which acts both as a
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buffer in the body and as a solution buffer [1]. The use of
bicarbonate-based solutions in peritoneal dialysis (PD)
has only recently become possible as a result of the de-
velopment of a two-chambered bag system to separate
calcium and magnesium from bicarbonate [2, 3]. This de-
livery system permits bicarbonate-based solutions con-
taining physiologic concentrations of bicarbonate to be
administered at a physiologic pH of 7.4 and an associated
physiologic pCO2. The two chambers also allow the ster-
ilization of glucose at low pH, which reduces the level of
glucose degradation products in the solution. These fea-
tures of the two-chambered bag system have been shown
to improve peritoneal cell function [abstract; Dawnay A,
J Am Soc Nephrol 10:312A, 1999] [4–6].
Although bicarbonate has been considered the “ideal”
buffer, studies in the early 1990s indicated that a PD solu-
tion based on a mixture of bicarbonate and lactate may be
more biocompatible than one comprised of bicarbonate
alone [7, 8]. Hence, a combination of 25 mmol/L bicar-
bonate and 10 or 15 mmol/L L-lactate was proposed [2,
9]. The bicarbonate concentration of this balanced formu-
lation was selected because it is the physiologic plasma
level. The addition of 10 or 15 mmol/L L-lactate helps
maintain acid-base balance. The pCO2 of this formula-
tion is at the physiologic level (48 mm Hg), as is the
pH (7.4). The 2 solutions also contain differing levels
of calcium, 1.75 mmol/L in the 25 mmol/L bicarbonate
and 10 mmol/L lactate solution and 1.25 mmol/L in the
25 mmol/L bicarbonate and 15 mmol/L lactate solution,
mirroring the composition of the standard lactate-based
solutions. A dialysis fluid with lower calcium content may
be needed by patients who require larger oral doses of
a calcium-containing phosphate binder. Conversely, pa-
tients who are hypocalcemic require a solution with a
higher calcium concentration. Both bicarbonate/lactate
solutions have been extensively studied in continuous
ambulatory peritoneal dialysis (CAPD) patients [2, 9–
12], and were shown to provide the following benefits:
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reduced infusion pain, better correction of acidosis, im-
proved ultrafiltration, improved symptoms (including im-
proved sense of well-being), and reduced duration of
peritonitis [abstract; Sprosen TS, Perit Dial Int 22(1):48,
2002].
Automated peritoneal dialysis (APD) is one of the
fastest-growing modalities for renal replacement therapy.
Currently, about 23,500 patients are being treated with
PD in Europe, and approximately 7100 of these are being
treated using the APD technique. Improving technology
and an increasing patient demand for APD will cause
a further significant increase in the use of this dialysis
modality. Patients on APD usually receive a larger to-
tal volume and more frequent, but shorter, exchanges of
dialysis fluid, and are likely to benefit more than patients
on CAPD from the use of such physiologic solutions be-
cause of the more frequent exposure of the peritoneal
membrane to acidic dialysis solutions.
The results of 2 studies of bicarbonate/lactate-based
PD solutions in an APD population are presented here.
In Study A, patients switched from a control solution con-
taining 40 mmol/L lactate to a bicarbonate/lactate solu-
tion containing an equivalent buffer content [25 mmol/L
bicarbonate + 15 mmol/L lactate (bicarbonate/lactate
40)]. In Study B, patients were using either 35 or 40 mmol/
L lactate solution at baseline and switched to a 25 mmol/L
bicarbonate + 10 mmol/L lactate solution (bicarbon-
ate/lactate 35) for the treatment period. Because the so-
lutions with the higher levels of buffer also contained
lower levels of calcium, patients switching from lactate
40 mmol/L to bicarbonate/lactate 35 (Study B) also ex-
perienced a change from 1.25 to 1.75 mmol/L calcium
(Fig. 1).
METHODS
Study design
Both studies (A and B) were nonrandomized, prospec-
tive, controlled, open-label multicenter comparisons of
two new PD solutions containing 25 mmol/L bicarbonate/
10 or 15 mmol/L lactate (study) with a standard solution
containing 35 or 40 mmol/L lactate (control). The 6-week
treatment period (study) was preceded by a 2-week base-
line period (control), and followed by a 2-week follow-up
period (control). All comparisons were made to base-
line, and each patient acted as his/her own control. Previ-
ous randomized studies incorporating a parallel control
group have confirmed that the magnitude of the change
from control (lactate) baseline is the same as the differ-
ences between the control and treatment group [11].
Study solutions
The study solutions were provided in two-chambered
bags and contained 25 mmol/L bicarbonate and ei-
ther 10 mmol/L lactate (total buffer 35 mmol/L;
Physioneal35, Baxter SpA, Sesto Fiorentino, Italy) or
15 mmol/L lactate, (total buffer 40 mmol/L; Physioneal
40, Baxter SpA). The control solutions contained 35 or
40 mmol/L lactate (Dianeal PD1, or Dianeal PD4, re-
spectively, Baxter Healthcare, Ltd., Castlebar, Ireland).
The compositions of the 4 solutions are given in Table 1.
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Table 1. The composition of the study solutions
Solution
Dianeal PD1 Dianeal PD4 Physioneal 35 Physioneal 40
(lactate 35) (lactate 40) (Bicarbonate/lactate 35) (Bicarbonate/lactate 40)
Sodium mmol/L 132 132 132 132
Calcium mmol/L 1.75 1.25 1.75 1.25
Magnesium mmol/L 0.75 0.25 0.25 0.25
Chloride mmol/L 102 95 101 95
Bicarbonate mmol/L 0 0 25 25
Lactate mmol/L 35 40 10 15
Dextrose anhydrous % 1.36, 2.27, and 3.86 1.36, 2.27, and 3.86 1.36, 2.27, and 3.86 1.36, 2.27, and 3.86
pH 5.5 5.5 7.4 7.4
pCO2 mm Hg 4 4 48 48
All solutions manufactured by Baxter Healthcare.
All products were manufactured according to normal
commercial procedures. The lactate-based products were
provided in a 5 L bag and the Physioneal products in a
2.5 L bag, which was the largest size manufactured at the
time the study was conducted.
Study population
The studies took place in 10 dialysis centers in the
United Kingdom, 9 in France, 2 in The Netherlands, and
2 in Belgium. A total of 96 eligible patients (46 in Study A
and 50 in Study B) were recruited. Each patient gave writ-
ten informed consent prior to participation, and approval
for the study was given by the local ethics committee for
each center. This trial conformed to the Declaration of
Helsinki and the Good Clinical Practice guidelines for
clinical trials in the European Union [13].
Prior to entry in the study, patients had been on APD
(7 days per week) using a 35 or 40 mmol/L lactate dialysis
solution (DianealPD1 or PD4) for at least 2 months and
HomeChoiceTM APD system (Baxter Healthcare Corpo-
ration, Deerfield, IL, USA) for at least 1 month. Their
total weekly creatinine clearance (peritoneal and renal)
was ≥55 L/1.73m2 body surface area as determined by
the PD AdequestTM program (Baxter Healthcare, ver-
sion 2.0a). Creatinine clearance, rather than Kt/V urea,
was used as an indicator of adequacy because this was the
most commonly used method in the participating centers.
Patients were excluded if they had completed a course
of antibiotics for peritonitis in the previous 30 days; had
other serious illnesses including the need for hospital-
ization in the previous 30 days; were pregnant or lactat-
ing; or were adding bicarbonate to the dialysis bags, or
taking bicarbonate orally and judged not able to discon-
tinue oral bicarbonate use for the duration of the study.
Patients receiving supplemental bicarbonate (intraperi-
toneally or orally) were excluded because such use would
affect plasma bicarbonate levels. In Study B, patients in
the group who received lactate 40 at baseline and were to
switch to bicarbonate/lactate 35 were excluded if they had
a serum calcium level above the upper limit of the nor-
mal range (2.6 mmol/L). Also excluded were patients with
significant acid/base disturbances (metabolic alkalosis or
respiratory acidosis). For further standardization, all pa-
tients used the icodextrin-containing solution Extraneal
(Baxter Healthcare) for the long dwell (8–12 hours) dur-
ing the 30 days prior to baseline, and during the base-
line, treatment, and follow-up periods. Extraneal contains
40 mmol/L lactate and 1.75 mmol/L calcium, and has a pH
of 5.2. No other dialysis solutions were allowed.
Study procedures
After giving informed consent, patients were treated
with the prescribed lactate-based dialysis solution for a
2-week (baseline) period, switched to the designated bi-
carbonate/lactate solution for the 6-week study period,
and then switched back to the same prescribed lactate-
based solution for follow-up period. The dialysis pre-
scription was to be kept constant, although patients were
permitted to make day-to-day changes in the glucose con-
tent of the daytime dialysis fluids to control ultrafiltration.
A medical history was taken and a physical examina-
tion was performed at baseline (week –2) and a medi-
cal update (recording all changes in medication, symp-
tom profile, and dialysis prescription) was completed at
each subsequent visit (weeks 0, 2, 4, 6, and 8). The phys-
ical examination was repeated at week 6. A product use
questionnaire was administered at week 6 in Study A.
Blood samples were taken at every visit and analyzed
at the local hospitals for sodium, potassium, total and
ionized calcium, phosphate, magnesium, urea, creatinine,
glucose, albumin, and C-reactive protein (CRP). Parathy-
roid hormone (PTH) levels were determined at week −2
and week 6 in Study B only (because of the difference
in calcium content between the lactate 40 and bicarbon-
ate/lactate 35 solutions). Plasma bicarbonate was mea-
sured in venous blood samples taken anaerobically. These
samples were analyzed in a blood gas analyzer within
15 minutes of sampling for actual bicarbonate, pCO2,
total CO2, and pH. The use of this technique enabled
standardization of this measurement across centers. The
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normal range used to establish acid-base status was 24–
30 mmol/L [14]. Venous, rather than arterial samples were
taken because it was regarded as unethical to expose pa-
tients to arterial punctures as part of a clinical trial when
properly taken venous samples can give adequate and
reproducible results [15].
Twenty-four hour urine volume and peritoneal ultra-
filtration (from HomeChoice PRO readouts or diary in-
formation) were measured and calculated prior to entry
into the study and at week 6. Dialytic bicarbonate and
lactate losses and gains were not determined in this study
but have been determined previously [2].
Statistical analysis
A repeated measures model using analysis of covari-
ance (ANCOVA)was used to estimate the change from
baseline and standard error for plasma bicarbonate. The
baseline value, defined as the patient’s average from the
control period (week –2 and day 0), was the covariate for
each patient. The overall mean change and its standard er-
ror were used to construct a 90% CI and evaluate whether
the changes in plasma bicarbonate were within 3 mmol/L
of the baseline value. This range was used because it is
commonly accepted that a change of 3 mmol/L signals a
clinically relevant change in the acid-base status and is
outside the normal range of intrapatient variability and
accuracy of the methodology [16]. Changes from the pre-
treatment control period to the bicarbonate/lactate pe-
riod were calculated for 24-hour ultrafiltration and paired
t tests were used to test for significant mean changes or
to establish equivalence. An analysis was done to deter-
mine the number of patients and values within the normal
range for venous plasma bicarbonate. A chi-square test
was performed to compare between the proportions from
the pretreatment and the bicarbonate/lactate treatment
periods.
Summary statistics such as means, standard deviations,
and ranges at each time point, including the follow-up
phase, were reported for the continuous safety variables
of vital signs and laboratory parameters. Simple compar-
isons for change between the control and test periods (i.e.,
change from baseline) were made using paired t tests.
RESULTS
Demographics
Analyses were performed on the intent-to-treat (ITT)
population [i.e., all patients who started the study and
received at least one dose of study medication (46 pa-
tients in Study A and 47 patients in Study B)], and the
per protocol group (patients with confounding factors
such as changes in dialysis prescription or changes in
the use of calcium-containing phosphate binders were
excluded). The per protocol group totaled 38 patients
in Study A and 34 patients in Study B. Baseline demo-
graphics of the ITT population are shown in Table 2. A
total of 73 patients completed the studies (35 in Study
A and 38 in Study B). Reasons for withdrawal included
peritonitis (7), renal transplantation (5), patient decision
(5), adverse event (4), death (diabetic calciphylaxis, 1),
and transfer to hemodialysis (1). Unless otherwise stated,
data shown are from the ITT analysis.
Venous plasma bicarbonate and other blood
gas parameters
Study A. The switch from lactate 40 to the bicarbon-
ate/lactate 40 resulted in an overall rise in plasma bi-
carbonate of 1.73 mmol/L (CI, 1.27 to 2.28, P < 0.001,
Table 3). The mean baseline plasma bicarbonate level
was 27.61 mmol/L and the peak mean on-treatment value
was 29.57 at week 4. The increase was more pronounced
at higher solution volumes (≥15 L), but was statistically
significant at all volumes (Table 3).
Study B. Similar to Study A, patients who switched
from the lactate 35 solution to the bicarbonate/lactate
35 solution experienced an overall rise in plasma bi-
carbonate of 2.06 mmol/L (CI, 1.32 to 2.79, P < 0.001,
Table 3). The mean baseline plasma bicarbonate level was
23.87 mmol/L and the peak mean on-treatment value at
week 2 was 26.1. As in Study A, the effect was statis-
tically significant at all solution volumes, but was more
pronounced at higher volumes (Table 3).
In the group of patients switching from the lactate 40
solution to the bicarbonate/lactate 35 solution, an overall
decrease in plasma bicarbonate of 1.16 mmol/L was seen
(CI, –1.74 to –0.57, P < 0.001, Table 3). The mean base-
line plasma bicarbonate level was 27.40 mmol/L and the
lowest mean on-treatment value was 25.70 at week 4. In
this group of patients, the fall in plasma bicarbonate was
only statistically significant in those patients using larger
volumes (≥15 L/24 hours, Table 3).
In all studies and groups, and in the per protocol group
(data not shown), changes in venous plasma bicarbon-
ate remained within the predefined ±3 mmol/L range of
the baseline value and were reflected in other blood gas
parameters, namely total CO2 and pH.
Normalization of plasma bicarbonate
In Study A, the percentage of plasma bicarbonate val-
ues below the normal range decreased (8.8% pretreat-
ment to 3.3% on treatment, P =NS), while the proportion
of values above the normal range increased (16.5% vs.
36.1%, respectively, P = 0.002, Fig. 2). The percentage
of values in the normal range also decreased (60.7% vs.
74.7%, respectively, P = 0.031).
The results of Study B indicated that more plasma
bicarbonate values were within the normal range (24–
30 mmol/L) during treatment with the bicarbonate/
lactate solution compared to the pure lactate solutions
(59.4% vs. 45.5%, respectively, for patients switching
from lactate 35 to bicarbonate/lactate 35, and 67.7% vs.
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Table 2. Baseline demographics of Study A and Study B intent-to-treat populations
Study B (n = 47) All switched to bicarbonate/lactate 35
Study A (N = 46) All switched
to bicarbonate/lactate 40 Lactate 40 group (N = 25) Lactate 35 group (N = 22)
Age years 57.2 53.6 51.5
Range min–max 18–86 26–78 25 –73
Body weight kg 74.3 74.9 76.0
Range min–max 47.0–125.4 49.7–103.4 51.5–108.0
Height cm 166.4 173.3 170.8
Range min–max 136.0–184.0 155.0–198.0 148.0–189.0
Males % 60.9 80.0 68.2
Primary renal disease
Glomerulonephritis 13 (28.3%) 9 (36%) 7 (31.8%)
Diabetic nephropathy 8 (17.4%) 2(12%) 3 (13.6%)
Hypertensive nephropathy 8 (17.4%) 1 (4%) 5 (22.7%)
Polycystic kidney disease — 1 (4%) 2 (9.1%)
Interstitial nephritis 6 (13.0%) 2 (8%) 1 (4.5%)
Obstructive nephropathy 1 (2.2%) — —
Autoimmune disease 1 (2.2%) — 1 (4.5%)
Other 9 (19.6%) 9 (36%) 3 (13.6%)
Mean duration of dialysis therapy months 41.1 40.9 53.5
Range min–max 3.6–166.8 4.3–241 3.6–266
All values are the mean. The intent-to-treat population is defined as those patients who started the treatment period and had values recorded during the treatment
period.
Table 3. Changes from baseline in plasma bicarbonate level, Study A and Study B intent-to-treat populations
95% CI
Total volume Mean of all
Treatment solution Baseline solution (including long dwell) N visits (mmol/L) Lower Upper P value
Study A Lactate 40 All patients 43 1.733 1.270 2.276 <0.001
Bicarbonate/lactate 40 <15 l 31 1.385 0.852 1.198 <0.001
≥15 l 12 2.486 1.680 4.013 <0.001
Study B Lactate 35 All patients 22 2.056 1.322 2.790 <0.001
Bicarbonate/lactate 35 <15 l 14 1.501 0.574 2.429 0.002
≥15 l 8 2.881 1.758 4.004 <0.001
Lactate 40 All patients 23 −1.157 −1.741 −0.572 <0.001
<15 l 11 −0.704 −1.521 0.113 0.088
≥15 l 12 −1.670 −2.490 −0.851 <0.001
The average change from baseline over the 3 visits (weeks 2,4,6) during treatment was used to determine if a significant change occurred. Baseline was the average of
the week −2 and day 1 values for each patient and assay. All values are the mean. The intent-to-treat population is defined as those patients who started the treatment
period, had values recorded during the treatment period, and took at least 1 dose of study solution.
62.0%, respectively, for patients switching from lactate
40 to bicarbonate/lactate 35) (Fig. 2). This difference was
statistically significant (P < 0.001) for the patients on
lactate 35 at baseline, but not for those on lactate 40,
although in the latter group there was a statistically
significant reduction in the number of alkalotic values
(venous bicarbonate values >30 mmol/L; 22% during
pretreatment vs. 7.7% on treatment, P < 0.001). Con-
versely, the number of acidotic values also increased
when patients switched from lactate 40 to the bicarbon-
ate/lactate 35 (20% vs. 6%, respectively), although this
difference was not statistically significant. A similar pat-
tern was observed when patients rather than values were
considered (data not shown).
Ultrafiltration
In Study A, a statistically significant increase in day-
time ultrafiltration volume of approximately 100 mL was
seen at weeks 2 and 4 (P < 0.05). In Study B, changes
from baseline in ultrafiltration were random and not
sustained.
Calcium, phosphate and parathyroid hormone
(Study B only)
A statistically significant rise in total serum calcium
was seen in the subgroup of patients that switched from
a lactate solution containing 1.25 mmol/L calcium to a
bicarbonate/lactate solution containing a higher concen-
tration of calcium (1.75 mmol/L). During the treatment
period, the overall change from baseline in serum cal-
cium was 0.06 mmol/L (CI, 0.011 to 0.11 mmol/L, P =
0.018, ITT population, Table 4). These findings were not
reflected in the per protocol population where the change
from baseline was only 0.008 mmol/L and not statistically
significant (P = 0.732). There were no statistically signif-
icant changes to parathyroid hormone (PTH) or phos-
phate levels in this subgroup.
Other biochemical parameters
No clinically relevant changes in any laboratory vari-
able were noted in Study A, except for serum sodium,
which increased from 134.23 mmol/L to 135.12 mmol/L
at week 2 (P = 0.009).
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In Study B, in the subgroup that switched from lactate
40 to bicarbonate/lactate 35, serum potassium increased
from a mean baseline value of 4.0 mmol/L to 4.5 mmol/L
at week 8 (P = 0.031).
Statistically significant changes from baseline were
seen in the following parameters in patients switching
from lactate 35 to bicarbonate/lactate 35 (ITT): serum
sodium (rose from a mean baseline value of 136.0 mmol/L
to 137.1 mmol/L at week 4, P = 0.014); and serum mag-
nesium (decreased from a mean value at baseline of
Fig. 2. (A) Study A, lactate 40 to bicarbonate/lactate 40. Plasma bi-
carbonate values below, within, and above the normal range during
pretreatment control and bicarbonate/lactate treatment period visits.
(B) Study B, lactate 35 to bicarbonate/lactate 35. Plasma bicarbonate
values below, within, and above the normal range during pretreatment
control and bicarbonate/lactate treatment period visits. (C) Study B,
lactate 40 to bicarbonate/lactate 35. Plasma bicarbonate values below,
within, and above the normal range during pretreatment control and
bicarbonate/lactate treatment period visits. P < 0.05.
1.0 mmol/L to 0.7 mmol/L at week 6, P < 0.001, prob-
ably reflecting a difference in magnesium content of the
solutions—0.75 mmol/L in lactate 35 and 0.25 mmol/L in
bicarbonate/lactate 35).
Vital signs, physical examination, and other
safety parameters
There were no clinically or statistically significant
changes from baseline in vital signs or the results of
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Table 4. Changes from baseline in total serum calcium, Study B, lactate 40 intent-to-treat population
95% CI
Total volume Number of Mean over
(including long dwell) patients visits (mmol/L) Lower Upper P valuea
<15 l 11 0.018 −0.055 0.091 0.615
≥15 l 12 0.103 0.028 0.177 0.008
All patients 23 0.063 0.011 0.114 0.018
The average change from baseline over the 3 visits (weeks 2,4,6) during treatment was used to determine if a significant change occurred. Baseline was the average of
the week −2 and day 1 values for each patient and assay. All values are the mean. The intent-to-treat population is defined as those patients who started the treatment
period and took at least 1 dose of study solution.
aP value from analysis of variance with repeated measures.
physical examination in either study. In particular, there
were no significant changes in blood pressure.
The adverse event profile was similar to that seen
in previous studies of bicarbonate/lactate solutions in
CAPD patients. In Study A (lactate 40 to bicarbon-
ate/lactate 40), alkalosis was reported as an adverse re-
action in 4 patients. Neither acidosis nor alkalosis was
reported in Study B (switch from lactate 40 or 35 to bi-
carbonate/lactate 35). Peritonitis was reported in both
studies, and 2 of the events were thought potentially to
be related to therapy (twice as many connections using
2.5 L bags rather than the usual 5 L bags).
Product use questionnaire
A product use questionnaire was administered in Study
A to gather information on the ease of use of the
two-chambered bag in the automated peritoneal dialy-
sis (APD) setting. A similar questionnaire had been used
in 2 previous CAPD studies [9, 11]. The questionnaire
was not administered in Study B, because sufficient infor-
mation had been gathered by that time. A total of 39/46
patients completed the questionnaire. Most of the ques-
tions related to technical issues concerning the use of the
product and are not reported here.
Patients were asked, using an open-ended question, to
compare the new solution with their old one (Did you no-
tice anything different with the new solution compared
with the one you were using during the pre-study pe-
riod?). Ten of the 11 patients responding to this ques-
tion reported less pain or discomfort on infusion or drain.
Other comments included better drainage, feeling better
during dwell, and being less tired during dwell. Patients
were asked to provide other product-related comments,
also in response to an open-ended question. Of the 25 pa-
tients who volunteered comments in this section, 11 made
positive remarks about the bicarbonate/lactate solution
compared to their previous experience with a lactate-only
solution. These remarks included: lighter feeling in peri-
toneum, general improved general well-being, improved
appetite, less tiredness, increased urine output, better
sleeping (does not wake up due to abdominal pain),
can do more, and hardly any abdominal pain. Most of
the negative comments related to practical details of the
therapy (the need to use 2.5 L bags for the bicarbon-
ate/lactate solution compared to 5 L bags for the lactate
solution).
DISCUSSION
The results of these studies demonstrate the value of
having dialysis solutions with differing buffer and cal-
cium content in order to enhance individualization in
prescription management. Solutions with higher buffer
concentration (both lactate and bicarbonate/lactate) are
adequate for some patients, but others may experience
an overcorrection of acidosis. The majority of patients on
the lower buffer solutions are adequately corrected, but
some may remain acidotic. It has previously been demon-
strated that bicarbonate/lactate solutions correct acido-
sis in CAPD more efficiently than lactate-based solutions
[9, 11]. The reason for this more efficient buffering may
be the physiologic pH of the formulation, which means
the entire buffer is biologically active; about 3.5% of the
buffer in low pH lactate-based solutions is present as bi-
ologically inactive lactic acid [9]. In the current studies,
the effect of bicarbonate/lactate on acid-base correction
appears to be volume-related, with larger increases in
plasma bicarbonate being noted at volumes ≥15 L. The
reason for this volume effect is unclear, but it may be
related to increased uptake of buffer during more fre-
quent dialysis fluid exchanges with APD. The implication
to clinical practice is that some patients on larger volumes
of bicarbonate/lactate 40 may become overcorrected in
terms of acid-base status as illustrated by the 4 cases of al-
kalosis reported in Study A. During that study, a protocol
amendment was put in place restricting the recruitment
of new patients to those with plasma bicarbonate levels
below 30 mmol/L while using the lactate solution. No
further cases of alkalosis occurred after the amendment
was implemented. The present studies also showed that
bicarbonate/lactate 35 may be a suitable alternative for
patients with a high plasma bicarbonate level, as the level
decreased by 1.2 mmol/L on switching from a lactate-
based solution with 40 mmol/L buffer to the bicarbon-
ate/lactate solution with 35 mmol/L buffer.
The more efficient buffering action of the bicarbon-
ate/lactate solutions meant that the patients using lactate
35 at baseline were better corrected when switched to
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bicarbonate/lactate 35, since a larger percentage of
plasma bicarbonate values were within the normal range
when patients were using this solution. The Dialysis Out-
comes Quality Initiatives (DOQI) guidelines recommend
that low plasma bicarbonate levels be avoided; it should
be further noted that the mid-normal to high-normal
blood pH range better maintains nutritional status than
does the low-normal range [17]. Adequate control of
plasma bicarbonate seems to be achievable with bicar-
bonate/lactate 35, particularly in an APD population.
In agreement with earlier observations [9, 11], an im-
provement in symptoms was observed. Patients who had
not reported pain on infusion at baseline nevertheless re-
ported an improvement in pain and discomfort when us-
ing the bicarbonate/lactate solution. It is likely that many
patients using standard lactate-based solutions experi-
ence infusion pain/discomfort, but accept it as part of ther-
apy. New observations in these studies included the fact
that patients slept better when using bicarbonate/lactate,
partly because of reduced pain/discomfort. Patients also
noted an improvement in appetite, a finding that also has
been noted in an animal model of peritoneal dialysis [ab-
stract; Zheng ZH, Perit Dial Int 21(Suppl 2):S103, 2001].
As in all PD studies, episodes of peritonitis were re-
ported. In 2 cases, the investigators suspected that the
peritonitis might have been due to touch contamination
as a result of making the extra connections required when
using 2.5 L bags. The episodes were not attributed directly
to the use of the bicarbonate/lactate solutions, which may
in fact have a favorable effect on peritonitis incidence and
duration [abstract; Sprosen TS, Perit Dial Int 22(1):48,
2002].
The change in plasma calcium concentration was minor
(approximately 0.06 mmol/L), and there was no change
in PTH level. It is recognized that these were short-term
studies and the results need to be confirmed with long-
term observations.
Predicted changes also were observed in magnesium
levels when patients switched from lactate 35 (0.75 mmol/
L magnesium) to bicarbonate/lactate 35 (0.25 mmol/L
magnesium). The values obtained during the treatment
period were generally in the normal range, whereas more
values were above the normal range during the base-
line period when patients were using the pure lactate so-
lution. Hypermagnesemia has been reported to worsen
metabolic bone disease [18, 19]. Indeed, this ion tends to
accumulate in dialysis patients, and there is evidence that
patients using pure lactate solutions can develop mild hy-
permagnesemia [18].
The changes seen in serum potassium and sodium were
minor and are likely to be random findings, as they have
not been observed in other studies.
An improvement in daytime ultrafiltration was seen in
Study A (bicarbonate/lactate 40) but not in Study B (bi-
carbonate/lactate 35). A similar improvement has been
seen in one [11], but not other [9] previous studies of bi-
carbonate/lactate solutions. It may be that the high vari-
ability of this measurement makes it difficult to detect
relatively small changes.
Biocompatible solutions are an important develop-
ment in PD and their benefits have already been well
demonstrated in the CAPD population [2, 9–11]. In vitro
and in vivo studies of the continuous use of bicarbon-
ate/lactate solutions during CAPD have demonstrated
improved cell function, reduced inflammation, reduced
potential for membrane damage, and improvements in
host defense status [abstract; Dawnay A, J Am Soc
Nephrol 10:312A, 1999] [4–6]. In patients receiving dial-
ysis using the automated method, the peritoneal mem-
brane is exposed to even larger volumes of dialysis fluid
and at more frequent intervals than with patients using
CAPD. Heimbu¨rger et al [21] demonstrated that it takes
2 hours for the pH of an acidic lactate-based solution
to reach a physiologic level; 2 hours would be a typi-
cal exchange time for APD. Therefore, it is particularly
important to be able to prescribe biocompatible solu-
tions for this population to ensure that the peritoneal
cavity is bathed by a PD solution that is at physiologic
pH throughout the entire APD session. Two studies of
the use of bicarbonate/lactate solutions in APD have al-
ready been reported. One of these showed that the ten-
dency for peritoneal transport status to increase with the
use of a lactate-based solution is attenuated when a bi-
carbonate/lactate solution is used [abstract; Plum J, Perit
Dial Int 23(Suppl 1):S27, 2003]. The other study showed
an improvement in bicarbonate balance in children, but
no changes in urea or creatinine clearances [abstract; Van
de Walle J, Perit Dial Int 23(Suppl 1):S60, 2003].
The current studies have shown that bicarbon-
ate/lactate solutions may be used safely and effectively
in APD. The availability of 2 different formulations in re-
gard to buffer level and calcium concentration gives the
clinician greater prescribing flexibility for the control of
acidosis, as well as the maintenance of calcium balance.
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